title: [Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
abstract: The Austrian Society for Bone and Mineral Research routinely publishes evidence-based guidelines for the treatment of postmenopausal osteoporosis. The fully human monoclonal antibody denosumab (Prolia(®)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. Denosumab has been shown to reduce vertebral, non-vertebral,and hip-fracture risk effectively. Together with alendronate, risedronate, zoledronate, ibandronate, strontium ranelate, and raloxifene, denosumab constitutes an effective option in the treatment of postmenopausal osteoporosis.
authors.affiliation: Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Austria. hans.dimai@medunigraz.at
authors.forename: Hans Peter
authors.initials: HP
authors.lastname: Dimai
authors.forename: Peter
authors.initials: P
authors.lastname: Pietschmann
authors.forename: Heinrich
authors.initials: H
authors.lastname: Resch
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Preisinger
authors.forename: Astrid
authors.initials: A
authors.lastname: Fahrleitner-Pammer
authors.forename: Harald
authors.initials: H
authors.lastname: Dobnig
authors.forename: Klaus
authors.initials: K
authors.lastname: Klaushofer
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069448:Denosumab; D017277:Drug Approval; D005060:Europe; D019317:Evidence-Based Medicine; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D053245:RANK Ligand / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000069448:Denosumab